Lili Szabo

NELLY enables patient-centric drug prioritization through interpretable drug-conditioned gene weighting

A translational framework combining patient-centric benchmarking with a pan-cancer pharmacogenomic atlas of patient-derived organoids and a deep learning model integrating transcriptomic and chemical information to predict drug response and prioritize therapies is introduced, supporting NELLY as a promising framework for translationally relevant and interpretable drug response prediction in precision oncology.